- Advanced ARCUS Gene Editing Development for Clinical and Research Programs; In Vivo Gene Editing R&D Day Planned for Mid-2023 - Progressed Azer-cel and PBCAR19B Allogenic CAR T Clinical Studies; Program Updates Planned for Azer-cel and PBCAR19B - Advanced Wholly Owned, Preclinical PBGENE-HBV and

DURHAM, N.C. --(BUSINESS WIRE)--Mar. 2, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and

- Neil Leatherbury Appointed Senior Vice President, Head of CMC – - Derek Jantz , Ph.D., to Assume Advisory Position of Co-Founder and Chief Science Advisor – - Jeff Smith , Ph.D., Co-Founder and Chief Research Officer Continues to Lead Research Strategy and Day-to-Day Execution of the Research

DURHAM, N.C. --(BUSINESS WIRE)--Feb. 22, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C.

DURHAM, N.C. --(BUSINESS WIRE)--Jan. 9, 2023-- Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate

- FDA feedback signals the Company’s CMC plans shared are in alignment with Agency requirements and expectations - CMC regulatory feedback is a critical step in the pathway for development of azer-cel DURHAM, N.C. --(BUSINESS WIRE)--Jan. 6, 2023-- Precision BioSciences (Nasdaq: DTIL), a clinical

- Cryopreserved, Post-thaw CAR T Cell Composition and Effective CAR T Cell Dose are Predictive for Response to Treatment with Azer-cel - Peak CAR T Expansion, a Key Determinant of Durable Response, Strongly Correlated with Effective CAR T Dose DURHAM, N.C. --(BUSINESS WIRE)--Dec.

- Raymond F. Schinazi , Ph.D., to Step Down from Board of Directors and Continue as a Member of the Company’s Scientific Advisory Board (SAB) DURHAM, N.C. --(BUSINESS WIRE)--Nov. 10, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex

- Allogeneic CAR T Program Updates Planned for Late Q4 2022 or Early Q1 2023 - Abstract Showcasing Functional Attributes of Azer-cel (PBCAR1091) Accepted for Presentation at the 64 th   American Society of Hematology (ASH) Annual Meeting - Preclinical Research on In Vivo Gene Editing Programs

DURHAM, N.C. --(BUSINESS WIRE)--Nov. 3, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that an abstract on the effective cell dose and functional attributes

DURHAM, N.C. --(BUSINESS WIRE)--Nov. 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the third quarter 2022 and

DURHAM, N.C. --(BUSINESS WIRE)--Oct. 26, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an inducement grant for Michael Amoroso , President and Chief

- Oral and Poster Presentations to Highlight Preclinical Research for ARCUS® Gene Editing DURHAM, N.C. --(BUSINESS WIRE)--Oct. 11, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing

DURHAM, N.C. --(BUSINESS WIRE)--Sep. 22, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Cell & Genetic

DURHAM, N.C. --(BUSINESS WIRE)--Sep. 7, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C.